Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression

The molecular mechanism underlying the pathogenesis of the majority of cases of sporadic Alzheimer's disease (AD) is unknown. A history of stroke was found to be associated with development of some AD cases, especially in the presence of vascular risk factors. Reduced cerebral perfusion is a common vascular component among AD risk factors, and hypoxia is a direct consequence of hypoperfusion. Previously we showed that expression of the β-site β-amyloid precursor protein (APP) cleavage enzyme 1 (BACE1) gene BACE1 is tightly controlled at both the transcriptional and translational levels and that increased BACE1 maturation contributes to the AD pathogenesis in Down's syndrome. Here we have identified a functional hypoxia-responsive element in the BACE1 gene promoter. Hypoxia up-regulated β-secretase cleavage of APP and amyloid-β protein (Aβ) production by increasing BACE1 gene transcription and expression both in vitro and in vivo. Hypoxia treatment markedly increased Aβ deposition and neuritic plaque formation and potentiated the memory deficit in Swedish mutant APP transgenic mice. Taken together, our results clearly demonstrate that hypoxia can facilitate AD pathogenesis, and they provide a molecular mechanism linking vascular factors to AD. Our study suggests that interventions to improve cerebral perfusion may benefit AD patients.

[1]  M. Goldberg,et al.  Inhibition of Hypoxia-inducible Factor 1 Activation by Carbon Monoxide and Nitric Oxide , 1999, The Journal of Biological Chemistry.

[2]  Weihui Zhou,et al.  Leaky Scanning and Reinitiation Regulate BACE1 Gene Expression , 2006, Alzheimer's & Dementia.

[3]  J. Schneider,et al.  Relation of cerebral infarctions to dementia and cognitive function in older persons , 2003, Neurology.

[4]  R. Yan,et al.  Reticulon family members modulate BACE1 activity and amyloid-β peptide generation , 2004, Nature Medicine.

[5]  H. Qing,et al.  Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  L. Huang,et al.  Hypoxia-inducible Factor and Its Biomedical Relevance* , 2003, Journal of Biological Chemistry.

[7]  Bryan Maloney,et al.  Functional characterization of the 5′ flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Y. Li,et al.  The FASEB Journal • Research Communication Control of APP processing and A � generation level by , 2022 .

[9]  H. Vinters,et al.  Effects of Anoxia and Hypoxia on Amyloid Precursor Protein Processing in Cerebral Microvascular Smooth Muscle Cells , 2006, Journal of neuropathology and experimental neurology.

[10]  P. Curtin,et al.  A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Buxbaum,et al.  BACE (β-secretase) modulates the processing of APLP2 in vivo , 2004, Molecular and Cellular Neuroscience.

[12]  H. Cai,et al.  Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients , 2004 .

[13]  C. Peers,et al.  Altered processing of amyloid precursor protein in the human neuroblastoma SH‐SY5Y by chronic hypoxia , 2002, Journal of neurochemistry.

[14]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[15]  C. Masters,et al.  Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .

[16]  B. Ghetti,et al.  Neurobiology: Presenilin-1 mutations in Alzheimer's disease , 2000, Nature.

[17]  W. Markesbery,et al.  Cerebrovascular Pathology and Dementia in Autopsied Honolulu‐Asia Aging Study Participants , 2002, Annals of the New York Academy of Sciences.

[18]  Xiulian Sun,et al.  BACE2, as a novel APP θ‐secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  G. Lenzi,et al.  Delayed poststroke dementia , 2004, Neurology.

[20]  C. Peers,et al.  Altered processing of the amyloid precursor protein and decreased expression of ADAM 10 by chronic hypoxia in SH-SY5Y: no role for the stress-activated JNK and p38 signalling pathways. , 2004, Brain research. Molecular brain research.

[21]  I. Kohane,et al.  Gene regulation and DNA damage in the ageing human brain , 2004, Nature.

[22]  Lawrence S. Honig,et al.  Atherosclerosis and AD : Analysis of data from the US national Alzheimer's coordinating center. Author's reply , 2005 .

[23]  M. Halterman,et al.  Hypoxia-Inducible Factor-1α Mediates Hypoxia-Induced Delayed Neuronal Death That Involves p53 , 1999, The Journal of Neuroscience.

[24]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[25]  B. Hyman,et al.  Beta-secretase activity increases with aging in human, monkey, and mouse brain. , 2004, The American journal of pathology.

[26]  Myriam Bernaudin,et al.  HIF1 and oxygen sensing in the brain , 2004, Nature Reviews Neuroscience.

[27]  Hong Qing,et al.  Transcriptional Regulation of BACE1, the β-Amyloid Precursor Protein β-Secretase, by Sp1 , 2004, Molecular and Cellular Biology.

[28]  H. Qing,et al.  Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[30]  A. Hofman,et al.  Silent brain infarcts and the risk of dementia and cognitive decline. , 2003, The New England journal of medicine.

[31]  S. Kitazume,et al.  Alzheimer's β-secretase, β-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Maher,et al.  The Regulation of Glucose Metabolism by HIF-1 Mediates a Neuroprotective Response to Amyloid Beta Peptide , 2003, Neuron.

[33]  B. de Strooper,et al.  The Cell Adhesion Protein P-selectin Glycoprotein Ligand-1 Is a Substrate for the Aspartyl Protease BACE1* , 2003, Journal of Biological Chemistry.

[34]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. M. de la Monte,et al.  Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. , 2003, Journal of Alzheimer's disease : JAD.

[36]  B. Hyman,et al.  The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate* , 2005, Journal of Biological Chemistry.

[37]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[38]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[39]  R. Simon,et al.  Induction of Caspase-3-Like Protease May Mediate Delayed Neuronal Death in the Hippocampus after Transient Cerebral Ischemia , 1998, The Journal of Neuroscience.

[40]  Fred Plum,et al.  Temporal profile of neuronal damage in a model of transient forebrain ischemia , 1982, Annals of neurology.

[41]  T. Südhof,et al.  Cleavage of Amyloid-β Precursor Protein and Amyloid-β Precursor-like Protein by BACE 1* , 2004, Journal of Biological Chemistry.

[42]  R. Mohs,et al.  Cerebral infarcts in patients with autopsy-proven Alzheimer's disease , 1998, Neurology.

[43]  R. Nandhagopal,et al.  Thalamic disequilibrium syndrome after thrombolytic therapy for acute myocardial infarction , 2005, Neurology.